We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BrainsWay (BWAY) Strengthens South Korean Foothold With Deep TMS
Read MoreHide Full Article
BrainsWay Ltd. (BWAY - Free Report) has announced the expanded availability of its Deep Transcranial Magnetic Stimulation (Deep TMS) technology in South Korea. This latest development is expected to address the growing demand for advanced noninvasive neurostimulation treatments.
The company is encouraged by the sales growth momentum over the past few quarters. According to BrainsWay, the latest extended availability of this device is projected to elevate its installed base in the country to more than 20 Deep TMS systems, marking a significant milestone in the company's global expansion.
More Into the News
According to BrainsWay, the expanded access to Deep TMS aligns with its goal to address mental health globally. Deep TMS, delivered through a patented coil design within a patient-friendly helmet, targets affected brain structures with a magnetic field, stimulating crucial neural networks.
The technology's success in positively impacting mental health patients in South Korea underscores its effectiveness in addressing major depressive disorders, the primary indication for which it is currently cleared in the country.
Image Source: Zacks Investment Research
In this regard, we note that BrainsWay's commitment to superior science is evidenced by its three FDA-cleared indications, including major depressive disorders, obsessive-compulsive disorders and smoking addiction.
Global Expansion in Noninvasive Neurostimulation
BrainsWay plays a prominent role in advanced noninvasive neurostimulation treatments globally. With offices in Burlington, MA, and Jerusalem, Israel, the company is dedicated to increasing global awareness and access to Deep TMS. As the technology continues to make strides in South Korea, BrainsWay solidifies its role as a transformative force in mental health, poised for continued progress and impact on a global scale.
Market Prospects
According to a Strategic Market Research report, the global neurostimulation device market is expected to witness a CAGR of 12.8%, reaching $5.41 billion in 2022 and is projected to soar to $50.7 billion by 2030.
The market is fueled by the rising awareness of mental diseases, a surge in neurological disorders and a growing aging population globally. Non-invasive treatments, the acknowledgment of neurostimulation therapies and the prevalence of chronic pain in the elderly contribute to the increasing demand for neurostimulation devices.
Share Price Performance
Shares of BWAY surged 206.2% in the past year against the industry’s 5.8% decline.
Zacks Rank and Other Key Picks
BrainsWay currently carries a Zacks Rank #2 (Buy).
Haemonetics’ stock has increased 3.9% in the past year. Earnings estimates for Haemonetics have increased from $3.86 to $3.89 in 2023 and $4.11 to $4.15 in 2024 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%.
Estimates for Insulet’s 2023 earnings per share have increased from $1.90 to $1.91 in the past 30 days. Shares of the company have dropped 35.6% in the past year compared with the industry’s decline of 5.8%.
PODD’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%.
Estimates for DexCom’s 2023 earnings per share have increased from $1.41 to $1.43 in the past 30 days and to $1.44 in the past seven days. Shares of the company have increased 2.1% in the past year compared with the industry’s decline of 5.1%.
DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Shutterstock
BrainsWay (BWAY) Strengthens South Korean Foothold With Deep TMS
BrainsWay Ltd. (BWAY - Free Report) has announced the expanded availability of its Deep Transcranial Magnetic Stimulation (Deep TMS) technology in South Korea. This latest development is expected to address the growing demand for advanced noninvasive neurostimulation treatments.
The company is encouraged by the sales growth momentum over the past few quarters. According to BrainsWay, the latest extended availability of this device is projected to elevate its installed base in the country to more than 20 Deep TMS systems, marking a significant milestone in the company's global expansion.
More Into the News
According to BrainsWay, the expanded access to Deep TMS aligns with its goal to address mental health globally. Deep TMS, delivered through a patented coil design within a patient-friendly helmet, targets affected brain structures with a magnetic field, stimulating crucial neural networks.
The technology's success in positively impacting mental health patients in South Korea underscores its effectiveness in addressing major depressive disorders, the primary indication for which it is currently cleared in the country.
Image Source: Zacks Investment Research
In this regard, we note that BrainsWay's commitment to superior science is evidenced by its three FDA-cleared indications, including major depressive disorders, obsessive-compulsive disorders and smoking addiction.
Global Expansion in Noninvasive Neurostimulation
BrainsWay plays a prominent role in advanced noninvasive neurostimulation treatments globally. With offices in Burlington, MA, and Jerusalem, Israel, the company is dedicated to increasing global awareness and access to Deep TMS. As the technology continues to make strides in South Korea, BrainsWay solidifies its role as a transformative force in mental health, poised for continued progress and impact on a global scale.
Market Prospects
According to a Strategic Market Research report, the global neurostimulation device market is expected to witness a CAGR of 12.8%, reaching $5.41 billion in 2022 and is projected to soar to $50.7 billion by 2030.
The market is fueled by the rising awareness of mental diseases, a surge in neurological disorders and a growing aging population globally. Non-invasive treatments, the acknowledgment of neurostimulation therapies and the prevalence of chronic pain in the elderly contribute to the increasing demand for neurostimulation devices.
Share Price Performance
Shares of BWAY surged 206.2% in the past year against the industry’s 5.8% decline.
Zacks Rank and Other Key Picks
BrainsWay currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space are Haemonetics (HAE - Free Report) , Insulet (PODD - Free Report) and DexCom (DXCM - Free Report) . Haemonetics and DexCom each presently carry a Zacks Rank #2, and Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Haemonetics’ stock has increased 3.9% in the past year. Earnings estimates for Haemonetics have increased from $3.86 to $3.89 in 2023 and $4.11 to $4.15 in 2024 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%.
Estimates for Insulet’s 2023 earnings per share have increased from $1.90 to $1.91 in the past 30 days. Shares of the company have dropped 35.6% in the past year compared with the industry’s decline of 5.8%.
PODD’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%.
Estimates for DexCom’s 2023 earnings per share have increased from $1.41 to $1.43 in the past 30 days and to $1.44 in the past seven days. Shares of the company have increased 2.1% in the past year compared with the industry’s decline of 5.1%.
DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%.